Coronary disease & ACSSecondary analysis
Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial
- Secondary analysis of the REVIVED-BCIS2 randomised trial
- prespecified analyses
- 40 UK centres
Authors' conclusion
PCI was not associated with a reduction in all-cause mortality or aborted sudden death. In patients with ischemic cardiomyopathy, PCI is not beneficial solely for the purpose of reducing potentially fatal ventricular arrhythmias.
Study context
- Population
- Patients with severe LV dysfunction, extensive coronary disease and viable myocardium
- Participants
- 700 patients
- Comparison
- Percutaneous coronary intervention (PCI) + OMT vs OMT alone
- PCI+OMTn = 347
- OMTn = 353reference
- Primary endpoint
- All-cause death or aborted sudden death (appropriate ICD therapy or resuscitated cardiac arrest), time to first event
- Follow-up
- Minimum of 24 months
Primary result
As reported in the abstract
Hazard ratio
1.03
95% CI 0.82–1.30
P = 0.80
Events by treatment group
PCI+OMT vs OMT
HR 1.03 (95% CI 0.82–1.30); P = 0.80
Secondary outcomes
CV death or aborted sudden death; appropriate implantable cardioverter defibrillator (ICD) therapy or sustained ventricular arrhythmia; number of appropriate ICD therapies
- No between-group difference in any secondary outcome
Original publication
Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial. Circulation. Published 9 August 2023. doi:10.1161/circulationaha.123.065300
Summarised from the published abstract; every number is checked against it